Telix Pharmaceuticals Ltd
TLXHealthcare|Biotechnology|Australia
$11.14
-0.65 (-5.47%)
Clinical Trials (34)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05847348 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer | P3 | Recruiting | 110 | Open-label | 68Ga-PSMA-11 |
| NCT07052214 PSMA PET Combined With MRI for the Detection of PCa | PCA, Prostate Cancer | P3 | Recruiting | 204 | Open-label | 68Ga-PSMA-11 |
| NCT07197580 Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | ccRCC, Renal Cell Carcinoma (Kidney Cancer) | P3 | Recruiting | 40 | RCT, Open-label | — |
| NCT06520345 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Metastatic Castration-resistant Prostate Cancer | P3 | Recruiting | 520 | RCT, Open-label | 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel |
| NCT07100730 Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | Neoplastic Disease, Glioblastoma | P3 | Recruiting | 50 | Open-label | — |
| NCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Clear Cell Renal Cell Carcinoma | P3 | Recruiting | 82 | Open-label | 89Zr-TLX250 PET/CT |
| NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer | Prostate Cancer | P2 | Recruiting | 50 | Open-label | PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC |
| NCT06447103 An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | P2 | Recruiting | 91 | Open-label | Zirconium Zr 89 Girentuximab |
| NCT05663710 Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | Advanced Cancer, Clear Cell Renal Cell Carcinoma | P1P2 | Recruiting | 100 | RCT, Open-label | 177Lu girentuximab, Nivolumab, Cabozantinib, ArabinoFuranosylGuanine [18F]F-AraG |
| NCT03762759 Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | Prostate Adenocarcinoma | P2 | Active | 140 | RCT, Open-label | Fluciclovine F18 |
| NCT06537596 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma | Soft Tissue Sarcoma | P1 | Recruiting | 50 | Open-label | 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) |
| NCT06044857 PSMA PET Response Guided SabR in High Risk Pca | Prostate Adenocarcinoma | P1 | Recruiting | 20 | Open-label | 68-Ga PSMA11 |
| NCT07197645 Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain | Bone Pain, Metastatic Bone Tumor | P1 | Recruiting | 33 | Open-label | 153Sm-DOTMP |
| NCT05868174 Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | Solid Tumor, Adult, Advanced Solid Tumor | P1 | Recruiting | 36 | Open-label | — |
| NCT05450744 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | Neoplastic Disease, Glioblastoma | P1 | Recruiting | 12 | Open-label | 131I-IPA |
| NCT04876651 The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | Metastatic Prostate Cancer | P3 | Terminated | 16 | RCT, Open-label | Standard of Care |
| NCT05744115 Ga-68-PSMA-11 in Men With Prostate Cancer | Prostate Cancer, Prostate Adenocarcinoma | P3 | Terminated | 38 | Open-label | Ga-68-PSMA-11 |
| NCT03849118 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study | Clear Cell Renal Cell Carcinoma | P3 | Completed | 300 | Open-label | — |
| NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | Cervical Cancer, Colorectal Cancer | P2 | Terminated | 11 | Open-label | — |
| NCT07077083 CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC | Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC | P2 | Not Yet Recruiting | 10 | Open-label | 89Zr-Girentuximab |
| NCT03849105 131I-IPA and Concurrent XRT in Recurrent GBM | Glioblastoma Multiforme | P1P2 | Completed | 10 | RCT, Open-label | — |
| NCT05146973 External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) | Prostate Cancer | P2 | Completed | 5 | Open-label | 177Lu-DOTA-TLX591 |
| NCT05861778 Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma | P1 | Completed | 10 | Open-label | 89Zr-Girentuximab |
| NCT03556046 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE | Clear Cell Renal Carcinoma | P1 | Completed | 10 | Open-label | — |
| NCT05046665 Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients | Urothelial Carcinoma | P1 | Completed | 11 | Open-label | 89Zr-Girentuximab |
| NCT04496089 Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC | Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma | P1 | Completed | 6 | Open-label | — |
| NCT04786847 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study | Metastatic Prostate Cancer | P1 | Completed | 30 | Open-label | 177Lu-DOTA-TLX591 |
| NCT07674771 Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery | Castrate Sensitive Prostate Cancer, Prostate Cancer | Early P1 | Not Yet Recruiting | 30 | Open-label | Drug: 68-Ga PSMA11, 68Ga-PSMA-11 |
| NCT06090331 89Zr-DFO-girentuximab Expanded Access Program (EAP) | Clear Cell Renal Cell Carcinoma | NO_LONGER_AVAILABLE | — | — | — | |
| NCT06743100 18F-Floretyrosine Expanded Access Program | Glioma (Any Grade) in the Brain | NO_LONGER_AVAILABLE | — | — | — | |
| NCT05558956 Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | Metastatic Castration-resistant Prostate Cancer | Early P1 | Unknown | 100 | RCT, Open-label | illuccix 68Ga-PSMA-11 Total Body PET-CT |
| NCT07238322 [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes | Retrospective Study, Glioma | Completed | 253 | — | — | |
| NCT06655064 Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations | Prostate Cancer (Adenocarcinoma) | Terminated | 120 | — | — | |
| NCT04726033 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) | Metastatic Prostate Cancer | Early P1 | Completed | 14 | Open-label | 64Cu-DOTA-TLX592 |